Trial reportObesity (Silver Spring, Md.)2023
Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.
Trial report in Obesity (Silver Spring, Md.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta-Analysis.European eating disorders review : the journal of the Eating Disorders Association · 2026Pooled it
- The weight reducing effects of naltrexone-bupropion among obese psychiatric and non-psychiatric patients: a systematic review.Psychopharmacology · 2025Pooled it
- Efficacy of naltrexone and bupropion combination in patients with binge eating disorder: a systematic review and meta-analysis.Eating and weight disorders : EWD · 2025Pooled it
- Naltrexone-bupropion for the treatment of binge eating disorder: a systematic review and meta-analysis.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2025Pooled it
- Cognitive-Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder: Secondary Outcomes of a Randomized Controlled Trial.The International journal of eating disorders · 2025Trial
- Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial.The American journal of psychiatry · 2025Trial
- Progressing Cross-Sector Collaboration for People With Eating Disorders and Higher Weight: Priority Actions From an Expert Roundtable Using a Modified Nominal Group Technique.The Medical journal of Australia · 2026Article
- Naltrexone/bupropion for binge-eating disorder: A human laboratory investigation of mechanisms.Drug and alcohol dependence reports · 2026Article
- Eating disorder psychopathology relates to weight loss medication and supplement use 6 months later in women.Eating and weight disorders : EWD · 2026Article
- Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Journal of endocrinological investigation · 2025Review
- Pharmacological management of binge eating disorder.The mental health clinician · 2025Article
- GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis.Journal of the Endocrine Society · 2025Review
- Novel potential pharmacological approaches in treating eating disorders comorbid with substance use disorders.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Endogenous opioid receptors and the feast or famine of maladaptive feeding.Nature communications · 2025Review
- Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications.Current obesity reports · 2025Review
- Obesity and psychology: a bibliometric analysis of half a century.Frontiers in nutrition · 2025Article
- Recent advances and prospects of nanoparticle-based drug delivery for diabetic ocular complications.Theranostics · 2025Review
- Reward and Inhibitory Control as Mechanisms and Treatment Targets for Binge Eating Disorder.Current psychiatry reports · 2024Review
- Review
- Psychopharmacology Review for Eating Disorders Among Children, Adolescents, and Adults.Focus (American Psychiatric Publishing) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveBinge-eating disorder (BED) is a prevalent psychiatric disorder associated with obesity. Few evidence-based treatments exist for BED, particularly pharmacological options. This study tested the efficacy of naltrexone/bupropion for BED.
methodsA randomized, double-blind, placebo-controlled, 12-week trial tested naltrexone/bupropion for BED with and without obesity. Eighty-nine patients (70.8% women, 69.7% White, mean age 45.7 y, mean BMI 35.1 kg/m
resultsMixed models of binge-eating frequency revealed significant reductions that did not differ significantly between naltrexone/bupropion and placebo. Logistic regression of binge-eating remission rates revealed that naltrexone/bupropion and placebo did not differ significantly. Obesity status did not predict, or moderate, binge-eating outcomes considered either continuously or categorically. Mixed models revealed that naltrexone/bupropion was associated with significantly greater percentage weight loss than placebo. Logistic regression revealed that naltrexone/bupropion had significantly higher rates of attaining ≥5% weight loss than placebo (27.9% vs. 6.5%). Obesity status did not predict or moderate weight-loss outcomes.
conclusionsNaltrexone/bupropion did not demonstrate effectiveness for reducing binge eating relative to placebo but showed effectiveness for weight reduction in patients with BED. Obesity status did not predict or moderate medication outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.